Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and DDI Study of ASP8477 in Healthy Volunteers
NCT02220777Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ASP8477 in neuropathic pain (4 arms), sponsored by Astellas Pharma. Primary endpoints: Safety and Tolerability, Maximum Plasma Concentration and 4 more. Started Nov 2010; status: completed.
02
Drugs
ASP8477
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT02220777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220777.